11 results on '"Moore, Ian N."'
Search Results
2. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
- Author
-
Corbett, Kizzmekia S., Werner, Anne P., Connell, Sarah O’, Gagne, Matthew, Lai, Lilin, Moliva, Juan I., Flynn, Barbara, Choi, Angela, Koch, Matthew, Foulds, Kathryn E., Andrew, Shayne F., Flebbe, Dillon R., Lamb, Evan, Nurmukhambetova, Saule T., Provost, Samantha J., Bock, Kevin W., Minai, Mahnaz, Nagata, Bianca M., Ry, Alex Van, Flinchbaugh, Zackery, Johnston, Timothy S., Mokhtari, Elham Bayat, Mudvari, Prakriti, Henry, Amy R., Laboune, Farida, Chang, Becky, Porto, Maciel, Wear, Jaclyn, Alvarado, Gabriela S., Boyoglu-Barnum, Seyhan, Todd, John-Paul M., Bart, Bridget, Cook, Anthony, Dodson, Alan, Pessaint, Laurent, Steingrebe, Katelyn, Elbashir, Sayda, Sriparna, Manjari, Pekosz, Andrew, Andersen, Hanne, Wu, Kai, Edwards, Darin K., Kar, Swagata, Lewis, Mark G., Boritz, Eli, Moore, Ian N., Carfi, Andrea, Suthar, Mehul S., McDermott, Adrian, Roederer, Mario, Nason, Martha C., Sullivan, Nancy J., Douek, Daniel C., Graham, Barney S., and Seder, Robert A.
- Abstract
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 µg of Moderna’s mRNA-1273 vaccine, a single immunization of 30 µg, or no vaccine. Two doses of 100 µg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log10reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log10reduction in nasal swabs in the 100-µg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.
- Published
- 2021
- Full Text
- View/download PDF
3. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
- Author
-
Saunders, Kevin O., Lee, Esther, Parks, Robert, Martinez, David R., Li, Dapeng, Chen, Haiyan, Edwards, Robert J., Gobeil, Sophie, Barr, Maggie, Mansouri, Katayoun, Alam, S. Munir, Sutherland, Laura L., Cai, Fangping, Sanzone, Aja M., Berry, Madison, Manne, Kartik, Bock, Kevin W., Minai, Mahnaz, Nagata, Bianca M., Kapingidza, Anyway B., Azoitei, Mihai, Tse, Longping V., Scobey, Trevor D., Spreng, Rachel L., Rountree, R. Wes, DeMarco, C. Todd, Denny, Thomas N., Woods, Christopher W., Petzold, Elizabeth W., Tang, Juanjie, Oguin, Thomas H., Sempowski, Gregory D., Gagne, Matthew, Douek, Daniel C., Tomai, Mark A., Fox, Christopher B., Seder, Robert, Wiehe, Kevin, Weissman, Drew, Pardi, Norbert, Golding, Hana, Khurana, Surender, Acharya, Priyamvada, Andersen, Hanne, Lewis, Mark G., Moore, Ian N., Montefiori, David C., Baric, Ralph S., and Haynes, Barton F.
- Abstract
Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (SARS-CoV-2)1–4. Vaccines that elicit protective immunity against SARS-CoV-2 and betacoronaviruses that circulate in animals have the potential to prevent future pandemics. Here we show that the immunization of macaques with nanoparticles conjugated with the receptor-binding domain of SARS-CoV-2, and adjuvanted with 3M-052 and alum, elicits cross-neutralizing antibody responses against bat coronaviruses, SARS-CoV and SARS-CoV-2 (including the B.1.1.7, P.1 and B.1.351 variants). Vaccination of macaques with these nanoparticles resulted in a 50% inhibitory reciprocal serum dilution (ID50) neutralization titre of 47,216 (geometric mean) for SARS-CoV-2, as well as in protection against SARS-CoV-2 in the upper and lower respiratory tracts. Nucleoside-modified mRNAs that encode a stabilized transmembrane spike or monomeric receptor-binding domain also induced cross-neutralizing antibody responses against SARS-CoV and bat coronaviruses, albeit at lower titres than achieved with the nanoparticles. These results demonstrate that current mRNA-based vaccines may provide some protection from future outbreaks of zoonotic betacoronaviruses, and provide a multimeric protein platform for the further development of vaccines against multiple (or all) betacoronaviruses.
- Published
- 2021
- Full Text
- View/download PDF
4. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
- Author
-
Corbett, Kizzmekia S., Edwards, Darin K., Leist, Sarah R., Abiona, Olubukola M., Boyoglu-Barnum, Seyhan, Gillespie, Rebecca A., Himansu, Sunny, Schäfer, Alexandra, Ziwawo, Cynthia T., DiPiazza, Anthony T., Dinnon, Kenneth H., Elbashir, Sayda M., Shaw, Christine A., Woods, Angela, Fritch, Ethan J., Martinez, David R., Bock, Kevin W., Minai, Mahnaz, Nagata, Bianca M., Hutchinson, Geoffrey B., Wu, Kai, Henry, Carole, Bahl, Kapil, Garcia-Dominguez, Dario, Ma, LingZhi, Renzi, Isabella, Kong, Wing-Pui, Schmidt, Stephen D., Wang, Lingshu, Zhang, Yi, Phung, Emily, Chang, Lauren A., Loomis, Rebecca J., Altaras, Nedim Emil, Narayanan, Elisabeth, Metkar, Mihir, Presnyak, Vlad, Liu, Cuiping, Louder, Mark K., Shi, Wei, Leung, Kwanyee, Yang, Eun Sung, West, Ande, Gully, Kendra L., Stevens, Laura J., Wang, Nianshuang, Wrapp, Daniel, Doria-Rose, Nicole A., Stewart-Jones, Guillaume, Bennett, Hamilton, Alvarado, Gabriela S., Nason, Martha C., Ruckwardt, Tracy J., McLellan, Jason S., Denison, Mark R., Chappell, James D., Moore, Ian N., Morabito, Kaitlyn M., Mascola, John R., Baric, Ralph S., Carfi, Andrea, and Graham, Barney S.
- Abstract
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirusspike proteins in the prefusion state, improving their expression and increasing immunogenicity1. This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant2SARS-CoV-2 as well as CD8+T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy.
- Published
- 2020
- Full Text
- View/download PDF
5. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice
- Author
-
Bohrer, Andrea C., Castro, Ehydel, Hu, Zhidong, Queiroz, Artur T.L., Tocheny, Claire E., Assmann, Maike, Sakai, Shunsuke, Nelson, Christine, Baker, Paul J., Ma, Hui, Wang, Lin, Zilu, Wen, du Bruyn, Elsa, Riou, Catherine, Kauffman, Keith D., Moore, Ian N., Del Nonno, Franca, Petrone, Linda, Goletti, Delia, Martineau, Adrian R., Lowe, David M., Cronan, Mark R., Wilkinson, Robert J., Barry, Clifton E., Via, Laura E., Barber, Daniel L., Klion, Amy D., Andrade, Bruno B., Song, Yanzheng, Wong, Ka-Wing, and Mayer-Barber, Katrin D.
- Abstract
Host resistance to Mycobacterium tuberculosis (Mtb) infection requires the activities of multiple leukocyte subsets, yet the roles of the different innate effector cells during tuberculosis are incompletely understood. Here we uncover an unexpected association between eosinophils and Mtb infection. In humans, eosinophils are decreased in the blood but enriched in resected human tuberculosis lung lesions and autopsy granulomas. An influx of eosinophils is also evident in infected zebrafish, mice, and nonhuman primate granulomas, where they are functionally activated and degranulate. Importantly, using complementary genetic models of eosinophil deficiency, we demonstrate that in mice, eosinophils are required for optimal pulmonary bacterial control and host survival after Mtb infection. Collectively, our findings uncover an unexpected recruitment of eosinophils to the infected lung tissue and a protective role for these cells in the control of Mtb infection in mice.
- Published
- 2021
- Full Text
- View/download PDF
6. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
- Author
-
Francica, Joseph R., Flynn, Barbara J., Foulds, Kathryn E., Noe, Amy T., Werner, Anne P., Moore, Ian N., Gagne, Matthew, Johnston, Timothy S., Tucker, Courtney, Davis, Rachel L., Flach, Britta, O’Connell, Sarah, Andrew, Shayne F., Lamb, Evan, Flebbe, Dillon R., Nurmukhambetova, Saule T., Donaldson, Mitzi M., Todd, John-Paul M., Zhu, Alex Lee, Atyeo, Caroline, Fischinger, Stephanie, Gorman, Matthew J, Shin, Sally, Edara, Venkata Viswanadh, Floyd, Katharine, Lai, Lilin, Boyoglu-Barnum, Seyhan, Van De Wetering, Renee, Tylor, Alida, McCarthy, Elizabeth, Lecouturier, Valerie, Ruiz, Sophie, Berry, Catherine, Tibbitts, Timothy, Andersen, Hanne, Cook, Anthony, Dodson, Alan, Pessaint, Laurent, Van Ry, Alex, Koutsoukos, Marguerite, Gutzeit, Cindy, Teng, I.-Ting, Zhou, Tongqing, Li, Dapeng, Haynes, Barton F., Kwong, Peter D., McDermott, Adrian, Lewis, Mark G., Fu, Tong Ming, Chicz, Roman, van der Most, Robbert, Corbett, Kizzmekia S., Suthar, Mehul S., Alter, Galit, Roederer, Mario, Sullivan, Nancy J., Douek, Daniel C., Graham, Barney S., Casimiro, Danilo, and Seder, Robert A.
- Abstract
Description
- Published
- 2021
- Full Text
- View/download PDF
7. Short stature and combined immunodeficiency associated with mutations in RGS10
- Author
-
Chinn, Ivan K., Xie, Zhihui, Chan, Eunice C., Nagata, Bianca M., Koval, Alexey, Chen, Wei-Sheng, Zhang, Fan, Ganesan, Sundar, Hong, Diana N., Suzuki, Motoshi, Nardone, Glenn, Moore, Ian N., Katanaev, Vladimir L., Balazs, Andrea E., Liu, Chengyu, Lupski, James R., Orange, Jordan S., and Druey, Kirk M.
- Abstract
Description
- Published
- 2021
- Full Text
- View/download PDF
8. Heme Oxygenase-1 Induction by Blood-Feeding Arthropods Controls Skin Inflammation and Promotes Disease Tolerance
- Author
-
DeSouza-Vieira, Thiago, Iniguez, Eva, Serafim, Tiago D., de Castro, Waldionê, Karmakar, Subir, Disotuar, Maria M., Cecilio, Pedro, Lacsina, Joshua R., Meneses, Claudio, Nagata, Bianca M., Cardoso, Silvia, Sonenshine, Daniel E., Moore, Ian N., Borges, Valeria M., Dey, Ranadhir, Soares, Miguel P., Nakhasi, Hira L., Oliveira, Fabiano, Valenzuela, Jesus G., and Kamhawi, Shaden
- Abstract
Hematophagous vectors lacerate host skin and capillaries to acquire a blood meal, resulting in leakage of red blood cells (RBCs) and inflammation. Here, we show that heme oxygenase-1 (HO-1), a pleiotropic cytoprotective isoenzyme that mitigates heme-mediated tissue damage, is induced after bites of sand flies, mosquitoes, and ticks. Further, we demonstrate that erythrophagocytosis by macrophages, including a skin-residing CD163+CD91+professional iron-recycling subpopulation, produces HO-1 after bites. Importantly, we establish that global deletion or transient inhibition of HO-1 in mice increases inflammation and pathology following Leishmania-infected sand fly bites without affecting parasite number, whereas CO, an end product of the HO-1 enzymatic reaction, suppresses skin inflammation. This indicates that HO-1 induction by blood-feeding sand flies promotes tolerance to Leishmaniainfection. Collectively, our data demonstrate that HO-1 induction through erythrophagocytosis is a universal mechanism that regulates skin inflammation following blood feeding by arthropods, thus promoting early-stage disease tolerance to vector-borne pathogens.
- Published
- 2020
- Full Text
- View/download PDF
9. Therapeutic responses to Roseomonas mucosain atopic dermatitis may involve lipid-mediated TNF-related epithelial repair
- Author
-
Myles, Ian A., Castillo, Carlo R., Barbian, Kent D., Kanakabandi, Kishore, Virtaneva, Kimmo, Fitzmeyer, Emily, Paneru, Monica, Otaizo-Carrasquero, Francisco, Myers, Timothy G., Markowitz, Tovah E., Moore, Ian N., Liu, Xue, Ferrer, Marc, Sakamachi, Yosuke, Garantziotis, Stavros, Swamydas, Muthulekha, Lionakis, Michail S., Anderson, Erik D., Earland, Noah J., Ganesan, Sundar, Sun, Ashleigh A., Bergerson, Jenna R.E., Silverman, Robert A., Petersen, Maureen, Martens, Craig A., and Datta, Sandip K.
- Abstract
Roseomonas mucosatreatment in children with atopic dermatitis is associated with clinical improvements and potentially lipid-mediated TNF signaling.
- Published
- 2020
- Full Text
- View/download PDF
10. Limited Pulmonary Mucosal-Associated Invariant T Cell Accumulation and Activation during Mycobacterium tuberculosisInfection in Rhesus Macaques
- Author
-
Kauffman, Keith D., Sallin, Michelle A., Hoft, Stella G., Sakai, Shunsuke, Moore, Rashida, Wilder-Kofie, Temeri, Moore, Ian N., Sette, Alessandro, Arlehamn, Cecilia S. Lindestam, and Barber, Daniel L.
- Abstract
Mucosal-associated invariant T cells (MAITs) are positioned in airways and may be important in the pulmonary cellular immune response against Mycobacterium tuberculosisinfection, particularly prior to priming of peptide-specific T cells. Accordingly, there is interest in the possibility that boosting MAITs through tuberculosis (TB) vaccination may enhance protection, but MAIT responses in the lungs during tuberculosis are poorly understood.
- Published
- 2018
- Full Text
- View/download PDF
11. In VivoImaging of Influenza Virus Infection in Immunized Mice
- Author
-
Czakó, Rita, Vogel, Leatrice, Lamirande, Elaine W., Bock, Kevin W., Moore, Ian N., Ellebedy, Ali H., Ahmed, Rafi, Mehle, Andrew, and Subbarao, Kanta
- Abstract
ABSTRACTImmunization is the cornerstone of seasonal influenza control and represents an important component of pandemic preparedness strategies. Using a bioluminescent reporter virus, we demonstrate the application of noninvasive in vivoimaging system (IVIS) technology to evaluate the preclinical efficacy of candidate vaccines and immunotherapy in a mouse model of influenza. Sequential imaging revealed distinct spatiotemporal kinetics of bioluminescence in groups of mice passively or actively immunized by various strategies that accelerated the clearance of the challenge virus at different rates and by distinct mechanisms. Imaging findings were consistent with conclusions derived from virus titers in the lungs and, notably, were more informative than conventional efficacy endpoints in some cases. Our findings demonstrate the reliability of IVIS as a qualitative approach to support preclinical evaluation of candidate medical countermeasures for influenza in mice.IMPORTANCEInfluenza A viruses remain a persistent threat to public health. Vaccination and immunotherapy are effective countermeasures for the control of influenza but must contend with antigenic drift and the risk of resistance to antivirals. Traditional preclinical efficacy studies for novel vaccine and pharmaceutical candidates can be time-consuming and expensive and are inherently limited in scope. In vivoimaging approaches offer the potential to noninvasively track virus replication in real time in animal models. In this study, we demonstrate the utility of bioluminescent imaging for tracking influenza virus replication in the lungs of immunized mice and also identify important factors that may influence the accurate interpretation of imaging results. Our findings support the potential of IVIS approaches to enhance traditional preclinical efficacy evaluation of candidate vaccines and human monoclonal antibodies for the prevention and treatment of influenza.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.